drugset / Trial / NCT06404333
Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)
Phase 2
Completed
13 enrolled
University of Oxford
ClinSearch · collabFundação de Dermatologia Tropical e Venereologia Alfredo da Matta (FUAM) · collabFundação de Medicina Tropical Dr. Heitor Vieira Dourado · collabUniversity of Basel · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The EPIC-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (CHILD-IVITAB) in scabies infected children weighing 5 to less than 15 kg. This trial will support future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15 kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of pediatric ivermectin therapy
Timeline
- Start
- 2025-02-25
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivermectin | Small molecule | 200 ug/kg | Oral |
| Subject | Ivermectin | Small molecule | 400 ug/kg | Oral |